Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
81-100 of 936 trials

Fronto-Temporal Dementia: LY3884963 Treatment Study

We are testing a new injection for patients with fronto-temporal dementia due to progranulin mutations. The study aims to evaluate its safety and effects on a key protein related to the disease.

Frontotemporal Dementia>2 yearsSafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Crohn's Disease: Multi-Donor Fecal Microbiota Transfer Study

We are investigating whether multi-donor fecal microbiota transfer can help maintain remission in children and adults with Crohn's disease after dietary treatment. The study will assess safety, feasibility, and quality of life for participants.

Crohn's Disease6-12 monthsSafety phase (I)Efficacy phase (II)Investigational MedicinesGastroenterologyPediatrics

Head and Neck Cancer: VB10.16 and Pembrolizumab

We are studying the safety and effectiveness of a new treatment combining VB10.16 with pembrolizumab for patients with HPV16-positive head and neck cancer. This trial aims to find the best dose and evaluate how well this combination works against the cancer.

Head and Neck Squamous Cell Carcinoma1-2 yearsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Advanced Solid Tumors: ODM-212 Study

We are testing a new oral medication, ODM-212, in patients with advanced solid tumors to evaluate its safety and how well it may work. This study aims to find the best dose and understand its effects on tumor growth.

Neoplasms (Tumors)>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Multiple Myeloma: HUVR-CARTemis-1 T-Cell Therapy

We are studying a new T-cell therapy for patients with multiple myeloma who have relapsed after an allogeneic transplant. The trial aims to evaluate the safety and effectiveness of this treatment over time.

Multiple Myeloma Progression>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Colorectal Cancer: CC-3 Antibody Study

We are testing a new bispecific antibody for patients with colorectal cancer to see if it is safe and effective. This is the first time this treatment is being evaluated in humans.

Progressive Metastatic Solid Cancer>2 yearsSafety phase (I)Oncology

Metastatic Breast Cancer: Elacestrant Combinations

We are evaluating the safety and effectiveness of Elacestrant in various combinations for patients with metastatic breast cancer. This study aims to find better treatment options for this condition.

Metastatic Breast Cancer>2 yearsSafety phase (I)Oncology

Metastatic Prostate Cancer: JNJ-78278343 Treatment Study

We are testing a new T-cell redirecting agent combined with other therapies for men with metastatic prostate cancer. The study aims to see if this combination can improve treatment results.

Metastatic Prostate Cancer>2 yearsSafety phase (I)OncologyUrology

Recurrent Solid Tumors: IMA402 Treatment Study

We are testing a new treatment called IMA402 for patients with recurrent or hard-to-treat solid tumors. The study aims to evaluate its safety and how well it works, both alone and with another medication.

Solid TumorsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

CAR123 T Cell Therapy for Blood Cancers

We are testing a new T cell treatment for patients with relapsed or refractory hematologic malignancies. The goal is to see if it can improve outcomes for those who have not responded to other therapies.

Relapsed/Refractory Blood CancersSafety phase (I)HematologyOncology

Advanced Solid Tumors: RO7589831 and Pembrolizumab

We are testing a new treatment combining RO7589831 with Pembrolizumab for people with advanced solid tumors. This study aims to understand how effective this combination may be in managing their condition.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Malignant Pleural Effusion: Pressurized Aerosol Chemotherapy

We are testing a new method of delivering chemotherapy directly into the chest for patients with malignant pleural effusion. This study aims to evaluate how well this treatment works and its safety.

Malignant Pleural Effusion>2 yearsSafety phase (I)OncologyPulmonology

Ewing Sarcoma: Regorafenib with Chemotherapy

We are studying a new combination of regorafenib and standard chemotherapy for patients with newly diagnosed multimetastatic Ewing sarcoma. The goal is to find the best dose and evaluate its safety and effectiveness.

Metastatic Ewing Sarcoma>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncologyOrthopedics and Traumatology

Chronic Myeloid Leukemia: ELVN-001 Treatment

We are investigating a new drug, ELVN-001, for patients with chronic myeloid leukemia. The goal is to see if it is safe and effective in treating this type of cancer.

Chronic Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Liver Problems: Study of Vimseltinib

We are investigating how the drug vimseltinib is processed in people with liver problems. This study aims to understand its absorption and effects in this group.

Tenosynovial Giant Cell Tumor (TGCT)Malignant Solid Tumors (MST)1-2 yearsSafety phase (I)HepatologyOncology

Cancer Treatment: Evaluating CC-486 in Liver Impairment

We are studying how CC-486 works in people with moderate or severe liver issues compared to those with normal liver function. This research aims to ensure safe and effective treatment options for cancer patients.

Myeloid MalignanciesSafety phase (I)HematologyHepatology

Light Chain Amyloidosis: Etentamig Treatment Study

We are evaluating the safety and effectiveness of Etentamig for individuals with Light Chain Amyloidosis. This study aims to understand how well this treatment works for managing the disease.

Light Chain Amyloidosis>2 yearsSafety phase (I)HematologyOncology

Prostate Cancer: VIR-5500 Treatment

We are studying the safety and early effects of VIR-5500 in men with prostate cancer. This trial aims to understand how well the treatment works and how it is processed in the body.

Hormone-Refractory Prostate Cancer>2 yearsSafety phase (I)Oncology

B-Cell Malignancies: Oral ABBV-101 Study

We are evaluating a new oral medication for adults with B-cell malignancies to see how it affects disease activity and its safety. This study will help us understand how the medication works in the body.

Non-Hodgkin's B-Cell Lymphoma>2 yearsSafety phase (I)HematologyOncology

Triple-Negative Breast Cancer: New Treatment Strategies

We are exploring new therapies for patients with early relapsed metastatic triple-negative breast cancer. The study aims to understand their safety and effectiveness compared to existing options.

Hormone-Receptor Negative and HER2-Negative Breast CancerSafety phase (I)Efficacy phase (II)Oncology